It appears an unintended side effect of the drug has now struck some of Britain's known suitmakers, who are fed up with ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.

Tirzepatide, the main ingredient in Mounjaro and Zepbound ... the main ingredient in the type 2 diabetes drug Ozempic and the weight loss drug Wegovy. Semaglutide remains on the FDA’s shortage ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health ...

Sam Darnold lofted a short pass to running back Cam Akers on third-and-2, sealing the win. The loss dropped the Packers to 11-5 this season. A respectable record, but all five losses have come against ...

Millions of obese Americans have achieved successful weight loss through use of glucagon-like peptide-1 agonists (GLP-1), a game-changing class of obesity medications. Results are often dramatic, but ...